AI brief
OpenAI is acquiring Orchestra Bio to apply AI-powered operations to life sciences research and development, aiming to help biopharma teams speed up drug development.
Why it matters: The acquisition extends OpenAI into AI tools for biopharma R&D.
Written by AI from OpenAI News's published text.
Background
From our own funding, model and news trackers, not from the source.
OpenAI
- Latest funding
- $30B · 31 Oct 2026
- Newest model on the API
- GPT-6.1 Terra Pro · 26 Oct 2026 · $1 in / $5 out per million tokens
Source
“OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.”
Published by the organisation it describes; treat claims as first-party statements.
Read original story ↗